Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Options Price in $280 Billion Earnings Swing 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Add as a preferred source on Google
HALIFAX, Nova Scotia, April 23, 2018 -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada.
Details of the presentation are as follows:
- Date: Thursday, May 3, 2018
- Time: 2:30 pm ET
- Location: Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada
About the Conference
Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest development in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology provides controlled and prolonged exposure to a broad range of immunogenic stimuli. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of its platform, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects in malaria and Zika virus. Connect at www.imvaccine.com.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: [email protected]
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: [email protected]
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: [email protected]
